These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. The EXAMINATION trial (Everolimus-Eluting Stents Versus Bare-Metal Stents in ST-Segment Elevation Myocardial Infarction): 2-year results from a multicenter randomized controlled trial. Sabaté M, Brugaletta S, Cequier A, Iñiguez A, Serra A, Hernádez-Antolín R, Mainar V, Valgimigli M, Tespili M, den Heijer P, Bethencourt A, Vázquez N, Backx B, Serruys PW. JACC Cardiovasc Interv; 2014 Jan; 7(1):64-71. PubMed ID: 24332423 [Abstract] [Full Text] [Related]
4. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. Sabaté M, Räber L, Heg D, Brugaletta S, Kelbaek H, Cequier A, Ostojic M, Iñiguez A, Tüller D, Serra A, Baumbach A, von Birgelen C, Hernandez-Antolin R, Roffi M, Mainar V, Valgimigli M, Serruys PW, Jüni P, Windecker S. JACC Cardiovasc Interv; 2014 Jan; 7(1):55-63. PubMed ID: 24332419 [Abstract] [Full Text] [Related]
5. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. Vink MA, Dirksen MT, Suttorp MJ, Tijssen JG, van Etten J, Patterson MS, Slagboom T, Kiemeneij F, Laarman GJ. JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625 [Abstract] [Full Text] [Related]
6. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. Kaltoft A, Kelbaek H, Thuesen L, Lassen JF, Clemmensen P, Kløvgaard L, Engstrøm T, Bøtker HE, Saunamäki K, Krusell LR, Jørgensen E, Tilsted HH, Christiansen EH, Ravkilde J, Køber L, Kofoed KF, Terkelsen CJ, Helqvist S. J Am Coll Cardiol; 2010 Aug 17; 56(8):641-5. PubMed ID: 20688033 [Abstract] [Full Text] [Related]
8. Long-term effects of drug-eluting stents versus bare metal stents on patients with acute ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: outcomes of 3-year clinical follow-up. Wang CH, Fang Q, Zhang SY, Shen ZJ, Fan ZJ, Jin XF, Zeng Y, Liu ZY, Xie HZ, Yang M. Chin Med J (Engl); 2012 Aug 17; 125(16):2803-6. PubMed ID: 22932070 [Abstract] [Full Text] [Related]
10. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, Ischinger T, Klauss V, Eberli F, Wijns W, Morice MC, Di Mario C, Corti R, Antoni D, Sohn HY, Eerdmans P, Rademaker-Havinga T, van Es GA, Meier B, Jüni P, Windecker S. JACC Cardiovasc Interv; 2013 Aug 17; 6(8):777-89. PubMed ID: 23968698 [Abstract] [Full Text] [Related]
11. Long-term comparison of sirolimus-eluting and bare-metal stents in ST-segment elevation myocardial infarction. Wijnbergen I, Tijssen J, Brueren G, Peels K, van Dantzig JM, Veer MV, Koolen JJ, Michels R, Pijls NH. Coron Artery Dis; 2014 Aug 17; 25(5):378-83. PubMed ID: 24736301 [Abstract] [Full Text] [Related]
13. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries. Simsek C, Magro M, Boersma E, Onuma Y, Nauta S, Daemen J, Gaspersz M, van Geuns RJ, van der Giessen W, van Domburg R, Serruys P. J Invasive Cardiol; 2011 Aug 17; 23(8):336-41. PubMed ID: 21828397 [Abstract] [Full Text] [Related]
17. Sirolimus-eluting stent versus bare metal stent in diabetic patients: the final five-year follow-up of the DIABETES trial. Jiménez-Quevedo P, Hernando L, Gómez-Hospital JA, Iñiguez A, SanRoman A, Alfonso F, Hernández-Antolín R, Angiolillo DJ, Bañuelos C, Escaned J, Gonzalo N, Fernández C, Macaya C, Sabaté M, DIABETES Investigators. EuroIntervention; 2013 Jul 01; 9(3):328-35. PubMed ID: 23518240 [Abstract] [Full Text] [Related]
19. Randomized comparison of everolimus-eluting stents and sirolimus-eluting stents in patients with ST elevation myocardial infarction: RACES-MI trial. Di Lorenzo E, Sauro R, Varricchio A, Capasso M, Lanzillo T, Manganelli F, Carbone G, Lanni F, Pagliuca MR, Stanco G, Rosato G, Suryapranata H, De Luca G. JACC Cardiovasc Interv; 2014 Aug 01; 7(8):849-56. PubMed ID: 25147029 [Abstract] [Full Text] [Related]
20. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries. Simsek C, Magro M, Boersma E, Onuma Y, Nauta ST, Gaspersz MP, van der Giessen WJ, van Domburg RT, Serruys PW, Interventional Cardiologists of the Thoraxcenter. JACC Cardiovasc Interv; 2010 Oct 01; 3(10):1051-8. PubMed ID: 20965464 [Abstract] [Full Text] [Related] Page: [Next] [New Search]